Galderma Laboratories

Galderma Laboratories Overview

Established in 1981 and headquarters in Lausanne, Switzerland. Galderma is one of the big names of the pharmaceutical industry in dermatology, over the past three decades galderma key area of focus is to provide innovative solutions in the field of dermatology, which consists of acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care.

Currently Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands.

Presently galderma is operating in over 80+ countries, providing patients with skin care needs and has an employee work force of over 6000 employees. The company has worldwide network of distributers and 34 wholly-owned affiliates.

Strategy

Galderma focuses on partnerships with different health-care practitioners across the world to meet the skin health needs of people. The company is also involved in the research and development of scientifically defined and medically-proven solutions for the skin to improve its product line. Moreover, with the recent acquisition of Galderma by a renowned consortium, the new management team focuses on a pureplay dermatology business, with outstanding prospects built on its existing quality portfolio, team and innovation.

Company Snapshot

$87,286.83M

Revenue

SWOT Analysis

Strengths

Worldwide distribution network
Highly skilled workforce
Robust R&D for the development of innovative products
Innovative product range
Trusted brand name
Global presence
Strong R&D base
Robust R&D capabilities
Considerable investment for research in aesthetic field
Presence in the global market
Strong R&D
Innovative products
Product approvals
Strong brand portfolio with broad range of medical and consumer health solutions. Well positioned for long-term growth in highly attractive dermatology sector with its refocus on food & nutrition since July 2019
Strong geographic presence with one of the best geographically diversified revenue sources. The company operates from 50 sites in 40 countries with 5 manufacturing sites and aims to increase the presence in the US and China, launch new products, and focus on international expansion
Expansion of the business by opening new business facility. Such as company opened new toxin manufacturing facility designed to meet the production and safety requirements of QM1114 liquid formulation of botulinum toxin type A
Positive pipeline growth with the clinical study ‘DREAM (Dysport Real-world Evaluation and Measured satisfaction’ with a 95% of patient’s high levels of satisfaction. Top-line results showed that 95% of patients treated with Dysport (abobotulinumtoxinA), and 97% of patients thought the result of the treatment looked natural
Proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries
Strong R&D activities
Well-established distribution network and global presence
Robust sales and marketing capabilities
Partnerships with major public and private organizations

Weaknesses

Past legal issues
Limited penetration in developing markets
Ceasing the operations of numerous factories in various regions such as Egerkingen
Limited presence in developing markets
Portfolio limited to the dermatology segment
Limited presence in emerging economies
Company is exposed to the recession and price risk mainly from investment in mutual funds and investment in equity
Limited success outside core businesses and one of the leading organizations in its industry but it has faced challenges in moving to other product segments
Need more investment for new technologies looking at the scale of expansion and different geographies the company is planning to expand into. Company needs to put more money in technology
Operational failures

Opportunities

Increasing the product portfolio
Mergers & acquisitions
Launch of new products
Strategic mergers & acquisitions
Enhancing the products portfolio by launching products
Collaborations with regional players to expand geographic boundaries
Collaboration with authorities, physicians and dermatologists to advance skin treatment. In 2016, Ipsen acquired the intellectual property for Galderma’s liquid toxin in some of the APAC region. The companies significantly strengthened their collaboration by prolonging their partnership until 2036 and increasing the scope of R&D
New environmental policies will create opportunities by creating a level playing field for the company in the industry. It represents a great opportunity for the company to drive home its advantages in new technology and gain market share in the new product category
Expansion of products offering
Acquisitions could strengthen growth rates and profitability

Threats

Negative consequences of healthcare reforms in major markets
Intense competition
Changing customer preference
Stringent government regulations
Intense competition in the botulinum toxin market by the presence of other major players in the market such as Allergan, Medytox, and Merz, among others to introduce new therapeutic applications of botulinum toxin
Fluctuating exchange rates, company is exposed to foreign currency risk arising out of transactions in foreign currency
Rising raw material price can pose a threat to the profitability of the company and changing consumer buying behavior which could be a threat to the existing physical infrastructure driven supply chain model

Key Developments

Date	Approach	Development
May 2018	Approval	Galderma received the Food and Drug Administration (FDA) approval for its Restylane Lyft a hyaluronic acid (HA) dermal filler for the back of the hands of patients over the age of 21
October 2017	Approval	Galderma received the FDA approval for Restylane Silk hyaluronic acid dermal filler. Restylane Silk is specially designed for lip augmentation and is injected via a cannula.
December 2016	Approval	Galderma received the FDA approval for the Restylane Refyne and Restylane Defyne dermal fillers used for laugh lines.
–	Partnership	Galderma, along with The European Society for Dermatological Research (ESDR), LEO Pharma, and Celgene partnered to form The Skin Science Foundation (SSF). The SSF will pioneer next-generation skincare by using cutting-edge techniques to better understand skin health.
–	Expansion	The company opened a new office in Kuala Lumpur, Malaysia, which will help the company to accelerate growth in this country.
–	Expansion	The parent company, Nestlé, launched two factories in the China Medical City in Taizhou, Jiangsu Province. With this expansion, the company increased its foothold in the Chinese market for facial fat transfer.
–	Approval	Galderma received the FDA approval for Restylane Silk hyaluronic acid dermal filler. Restylane Silk is specially designed for lip augmentation and is injected via a cannula. Thus, the company expanded its portfolio of products in the facial fat transfer market.
–	Expansion	The company invested 46 million Canadian dollars (USD 35.46 million) to extend the capacity of its Canadian factory located in Baie D’Urfé, Québec. Through this, the company strengthened its position in the Canadian market.
–	Expansion	The company invested 54 million Swiss Franc (USD 55.15 million) in a new skin health products factory in the Brazilian state of São Paulo, to meet the rising demand for facial aesthetic products in the country and across Latin America. Thereby bracing its position in the Latin American market.
May 2018	Product Approval	The FDA approved Restylane Lyft for treatment of wrinkles and folds. It was the first injectable filler (hyaluronic acid filler) used for wrinkles and folds which was approved by the FDA.
October 2019	Manufacturing License	Galderma SA received a manufacturing license to set up a new state-of-the-art manufacturing facility in Uppsala, Sweden. With this facility, the company will be able to cater to the needs of European customers.
January 2016	Agreement	Ipsen Pharma (France) and Galderma SA went into an agreement for the distribution of Dysport in the Asia-Pacific region. Galderma received product development, promotion and distribution rights of Dysport for the Asia-Pacific region.
December 2019	Approval	Galderma received and approval from the European Union (EU) for its AKLIEF for patients from 12 years of age and older.
October 2019	Approval	Galderma received the FDA approval for AKLIEF-containing retinoid molecule. It is the first retinoid molecule to receive approval for the treatment of acne in over 20 years.
January 2019	Expansion	Galderma announced the opening of a new office in Malaysia. With this, the company aims to accelerate growth in this region.

Product Offering

Galderma Laboratories
- Consumer Solutions
- Dermal Fillers
- Skin Senescence
- Medical Solutions
- Acne
- Melasma
- Seborrheic dermatitis
- Skin senescence
- Cosmetics

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.